APRE Aprea Therapeutics, Inc. Common stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
APRE
—
—
Key stats
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.35 |
| Cost of Equity (CAPM) | 11.72% |
| WACC | 11.88% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -32.0% |
| Book / Price | 416.7% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -234974.2% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $0.71 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.61 |
| Bollinger Width / SMA20 | 8546.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$3.28
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | $6.57 | 50% | median 3.5× · 3 peers |
| Peer P/S | $0.00 | 50% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $0.71 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 8
- List Date
- 2019-10-03
- CIK
- 0001781983
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($0.08) (2 est.)
- Headquarters
- Doylestown, PA
- Homepage
- https://www.aprea.com
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 16.70% | -33.86% | 33.73% | 3.40% | 9.52% | -6.68% | 3.80% |
| Feb | 4.33% | -20.18% | -48.71% | 48.42% | -33.78% | 22.10% | -4.64% |
| Mar | -15.42% | 7.51% | -14.62% | -16.37% | -11.69% | -13.81% | -10.73% |
| Apr | -6.94% | -21.08% | -5.37% | -19.69% | -9.37% | 13.65% | -8.13% |
| May | -9.05% | -43.79% | 0.13% | -9.14% | -3.87% | 9.12% | -9.43% |
| Jun | 7.73% | -1.96% | -13.93% | -14.32% | -6.11% | -1.67% | -5.04% |
| Jul | -21.96% | 23.87% | -4.26% | -10.17% | 3.03% | -12.80% | -3.71% |
| Aug | 7.94% | -16.41% | 19.35% | -7.33% | -5.72% | 33.85% | 5.28% |
| Sep | 8.03% | -16.68% | 10.22% | -17.42% | -6.05% | -10.25% | -5.36% |
| Oct | -0.50% | 1.82% | -16.21% | 50.38% | -4.11% | -37.94%* | -1.09% |
| Nov | -19.84% | -37.96% | 5.20% | -26.02% | -10.00% | -- | -17.72% |
| Dec | -24.87% | -18.61% | 27.03% | 5.45% | -23.15% | -- | -6.83% |
| Total | -48.80% | -89.05% | -32.65% | -35.29% | -68.29% | -22.14% | -49.37% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.61
SMA 50: $0.71
SMA 200: $0.76
Current: $0.45
EMA 12: $0.56
EMA 26: $0.62
MACD: -0.0590 | Signal: -0.0102
BEARISH
ADX (14): 18.32
RANGE
+DI: 15.30
−DI: 28.34
Momentum Oscillators
RSI (14): 26.77
OVERSOLD
Stoch %K: 14.94
Stoch %D: 17.05
Williams %R: -84.27
Volume & Volatility
BB Upper: $0.77
BB Lower: $0.45
OVERSOLD
OBV: 119,196,080
Vol SMA 20: 292,959
Vol ROC: 383.83%
ATR: $0.06
True Range: $0.11
HV 20: 84.0%
HV 30: 75.3%
HV 60: 90.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
APRE Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers:
- Consolidation phase after recent decline
- Technical indicators suggest a neutral trend
Primary Risks:
- Bearish momentum signals from MACD
- Recent news headlines not available, making it challenging to assess sentiment
Investment Thesis:
APRE is in a consolidation phase, with a mix of bearish and bullish technical signals. The stock has low volatility relative to the market, indicating a relatively stable trend. However, the lack of recent news highlights potential uncertainty.
Recent News Sentiment Impact: N/A (no recent news available)
Technical Analysis
Trend Direction: Neutral (short-term), Bearish (medium-term), Bullish (long-term)
Support/Resistance Levels:
- Short-term support: $1.41 (lower Bollinger Band)
- Medium-term resistance: $1.52 (upper Bollinger Band)
- Long-term support: $2.15 (SMA 200)
Momentum Signals:
- RSI (14): Neutral (41.02), indicating no clear buy or sell signal
- MACD: Bearish (negative histogram and signal line)
- Bollinger Bands: Neutral, with price near the middle band
Volume Analysis:
- Volume SMA 20: 49239.55 (stable volume trend)
- On-Balance Volume (OBV): 1411034.00 (no clear trend)
- Volume Rate of Change: 89.08% (moderate volume growth)
News & Sentiment Analysis
Recent Headlines Summary: N/A (no recent news available)
Sentiment Assessment: N/A (no recent news available)
Catalyst Identification: N/A (no recent news available)
Market Narrative: N/A (no recent news available)
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to the market (beta 0.64)
Volatility Regime: Low volatility regime, with stock moving less than the market
Options Market Signals:
- IV rank: N/A (no options data available)
- Put/call ratios: N/A (no options data available)
- Unusual activity: N/A (no options data available)
Downside Protection:
- Support levels: $1.41 (lower Bollinger Band), $2.15 (SMA 200)
- Risk management considerations: Stop-loss levels near the lower Bollinger Band and position sizing based on market conditions
Market Context & Positioning
Sector Performance: N/A (no sector data available)
Institutional Activity: N/A (no institutional activity data available)
Correlation Analysis: APRE has a relatively low correlation with the market (R-squared 0.16), indicating some independence from broader market trends.
Relative Valuation: APRE is trading within its historical range, suggesting no clear value or momentum-based investment thesis
Key Levels & Action Items
- Critical Price Levels: $1.41 (lower Bollinger Band), $2.15 (SMA 200)
- Breakout/Breakdown Levels: $1.52 (upper Bollinger Band) and $2.15 (SMA 200)
- Time-Sensitive Catalysts: Earnings dates, product launches, or regulatory changes
- Risk Management: Stop-loss levels near the lower Bollinger Band and position sizing based on market conditions
Note: The analysis is neutral due to the lack of recent news headlines and mixed technical signals. APRE's low volatility and stable trend suggest a relatively safe investment environment, but caution should be exercised due to the bearish momentum signals from MACD.
Generated
News
All APRE news →
Earnings History
3 of 8 under expected move
Avg Expected Move
27.43%
Avg Actual Move
8.94%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-16 | unknown | 0.81% | 3.58% | 4.42x | Exceeded |
| 2021-05-06 | unknown | 1.41% | 0.94% | 0.67x | Within |
| 2021-08-12 | unknown | 1.57% | 9.65% | 6.15x | Exceeded |
| 2021-11-08 | After-Close | 0.67% | 0.20% | 0.30x | Within |
| 2022-01-13 | Pre-Market | 5.18% | 6.88% | 1.33x | Exceeded |
| 2022-03-15 | After-Close | 3.65% | 14.37% | 3.94x | Exceeded |
| 2022-05-16 | unknown | 9.35% | 29.68% | 3.17x | Exceeded |
| 2023-05-15 | unknown | 196.77% | 6.20% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
APRE Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: —
7-DTE Move: —
Days to Exp: — (Unknown)
Options Flow
Call Volume: —
Put Volume: —
P/C Volume: —
Call OI: —
Put OI: —
P/C OI: —
Total OI: —
ATM Options Pricing
ATM Call: —
ATM Put: —
Call %: —
Put %: —
Chain Summary
Chain Volume: 0
Chain OI: 0
Last Updated: 1/19/2024
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Dec 22 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Dec 22 · ATM 18.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.8445
Alpha: -81.17%
Correlation: 0.1124
R-Squared: 1.3%
Stock Volatility: 95.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own APRE
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $85K | #2996 of 3138 | +321.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $47K | #6009 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
APRE Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 20,561,661 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
APRE Insider Trading (Form 4)
Latest: 2026-06-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Marc Duey | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | Richard Peters | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | Bernd R. Seizinger | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | Michael Grissinger | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | Gabriela Gruia | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | Rifat Pamukcu | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | John B Henneman III | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-06-17 | Jean-Pierre Bizzari | Director | Award (A) | +3,135 | — | EDGAR | |
| 2026-04-01 | Richard Peters | Director | Buy (P) | +247,830 RSU | — | EDGAR | |
| 2026-04-01 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy (P) | +61,956 RSU | — | EDGAR | |
| 2026-03-16 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Award (A) | +10,095 | — | EDGAR | |
| 2026-03-16 | Oren Gilad | President/CEO | Award (A) | +20,175 | — | EDGAR | |
| 2026-02-02 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy (P) | +5,700 | $0.89 | $5.1K | EDGAR |
| 2026-02-02 | Oren Gilad | President/CEO | Buy (P) | +28,100 | $0.89 | $25.0K | EDGAR |
| 2025-12-11 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy (P) | +5,000 | $1.17 | $5.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
APRE Insider Holdings
10 insiders · @ $0.45
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Oren Gilad | President/CEO | 395,095 | $177.4K | $55.4K | 12 | 2026-03-16 |
| 2 | Marc Duey | Director | 259,892 | $116.7K | $127.6K | 9 | 2026-06-17 |
| 3 | Bernd R. Seizinger | Director | 48,910 | $22.0K | $149.3K | 12 | 2026-06-17 |
| 4 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | 43,528 | $19.5K | $19.6K | 11 | 2026-04-01 |
| 5 | Rifat Pamukcu | Director | 22,689 | $10.2K | $0 | 5 | 2026-06-17 |
| 6 | John B Henneman III | Director | 13,364 | $6.0K | $125.0K | 9 | 2026-06-17 |
| 7 | Richard Peters | Director | 6,254 | $2.8K | $0 | 8 | 2026-06-17 |
| 8 | Michael Grissinger | Director | 6,024 | $2.7K | $0 | 5 | 2026-06-17 |
| 9 | Jean-Pierre Bizzari | Director | 4,180 | $1.9K | $0 | 3 | 2026-06-17 |
| 10 | Gabriela Gruia | Director | 4,180 | $1.9K | $0 | 3 | 2026-06-17 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
APRE Board & Officers
As of SEC filings through Jun 17, 2026Directors 7
- Bernd R. Seizinger · since Oct 2, 2019
- John B Henneman III · since Oct 2, 2019
- Richard Peters · since Jun 26, 2020
- Marc Duey · since May 16, 2022
- Michael Grissinger · since May 16, 2022
- Oren Gilad · since May 16, 2022
- Rifat Pamukcu · since May 16, 2022
Officers 2
- Oren Gilad · President/CEO · listed since Aug 2022
- John P. Hamill · SrVP/CFO/Prin Fin & Acct Ofcr · listed since Feb 2023
Changes in the last 10 years (94)
| May 1, 2024 | Nadeem Q. Mirza became Chief Medical Officer |
| Aug 23, 2023 | The company announced the departure of Jean-Pierre Bizzari from the board in an SEC filing |
| Aug 23, 2023 | The company announced the departure of Christian S Schade from the board in an SEC filing |
| Aug 23, 2023 | Jean-Pierre Bizzari became a director |
| May 5, 2023 | The company announced the departure of Gabriela Gruia from the board in an SEC filing |
| May 5, 2023 | Gabriela Gruia became a director |
| Feb 27, 2023 | John P. Hamill listed as SrVP/CFO/Prin Fin & Acct Ofcr (previously SrVP/CFO/Prin. Fin &Acctg. Off) in SEC filings |
| Jan 30, 2023 | The company announced the departure of Scott M Coiante as SVP, Chief Financial Officer in an SEC filing |
| Jan 30, 2023 | John P. Hamill became SrVP/CFO/Prin. Fin &Acctg. Off |
| Aug 1, 2022 | Oren Gilad listed as President/CEO (previously President) in SEC filings |
| Jun 7, 2022 | Gregory Alan Korbel listed as SVP, Chief Operating Officer (previously SVP, Chief Business Officer) in SEC filings |
| May 16, 2022 | The company announced the departure of Michael Aaron Kelly from the board in an SEC filing |
| May 16, 2022 | The company announced the departure of Fouad Namouni from the board in an SEC filing |
| May 16, 2022 | The company announced the departure of Eyal C. Attar as SVP, Chief Medical Officer in an SEC filing |
| May 16, 2022 | The company announced the departure of Christian S Schade as Chairman & CEO in an SEC filing |
| May 16, 2022 | Rifat Pamukcu became a director |
| May 16, 2022 | Oren Gilad became a director |
| May 16, 2022 | Oren Gilad became President |
| May 16, 2022 | Michael Grissinger became a director |
| May 16, 2022 | Marc Duey became a director |
| Mar 14, 2022 | Scott M Coiante first listed as a director in an SEC filing |
| Mar 14, 2022 | Gregory Alan Korbel first listed as a director in an SEC filing |
| Mar 14, 2022 | Eyal C. Attar first listed as a director in an SEC filing |
| Sep 22, 2021 | Gregory Alan Korbel listed as SVP, Chief Business Officer (previously Chief Business Officer) in SEC filings |
| Mar 11, 2021 | Gregory Alan Korbel listed as Chief Business Officer (previously VP of Business Dev't) in SEC filings |
| Mar 1, 2021 | Christian S Schade listed as Chairman & CEO (previously President & CEO) in SEC filings |
| Feb 16, 2021 | Redmile Group, LLC reported in an SEC filing no longer being a 10% owner |
| Feb 16, 2021 | Jeremy Green reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | Scott M Rocklage reported in an SEC filing no longer being a director |
| Oct 7, 2020 | Scott M Rocklage reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | Kush Parmar reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | John D Diekman reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | Andrew J. Schwab reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | 5AM Ventures IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | 5AM Partners IV, LLC reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | 5AM Opportunities I, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | 5AM Opportunities I (GP), LLC reported in an SEC filing no longer being a 10% owner |
| Oct 7, 2020 | 5AM Co-Investors IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 28, 2020 | Michael Aaron Kelly became a director |
| Sep 16, 2020 | Gregory S. Wessels became SVP, Chief Commercial Officer |
| Jul 7, 2020 | KDev Investments AB reported in an SEC filing no longer being a 10% owner |
| Jul 7, 2020 | KCIF Co-Investment Fund KB reported in an SEC filing no longer being a 10% owner |
| Jul 7, 2020 | Development AB Karolinska reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2020 | Richard Peters became a director |
| Jun 26, 2020 | Fouad Namouni became a director |
| Jun 15, 2020 | Scott M Rocklage first listed as a 10% owner in an SEC filing |
| May 20, 2020 | Versant Ventures V, LLC reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Ventures V (Canada), L.P. reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Venture Capital V, L.P. reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Venture Capital V (Canada), LP reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Vantage I, L.P. reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Vantage I GP-GP, LLC reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Vantage I GP, L.P. reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant V Luxco S.a r.l. reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Ophthalmic Affiliates I, L.P. reported in an SEC filing no longer being a 10% owner |
| May 20, 2020 | Versant Affiliates Fund V, L.P. reported in an SEC filing no longer being a 10% owner |
| Oct 9, 2019 | Kush Parmar first on file as a 10% owner |
| Oct 9, 2019 | 5AM Opportunities I, L.P. first on file as a 10% owner |
| Oct 9, 2019 | 5AM Opportunities I (GP), LLC first on file as a 10% owner |
| Oct 7, 2019 | Versant Vantage I, L.P. first on file as a 10% owner |
| Oct 7, 2019 | Versant Vantage I GP-GP, LLC first on file as a 10% owner |
| Oct 7, 2019 | Versant Vantage I GP, L.P. first on file as a 10% owner |
| Oct 2, 2019 | Versant Ventures V, LLC became a 10% owner |
| Oct 2, 2019 | Versant Ventures V GP-GP (Canada), Inc. became a 10% owner |
| Oct 2, 2019 | Versant Ventures V (Canada), L.P. became a 10% owner |
| Oct 2, 2019 | Versant Venture Capital V, L.P. became a 10% owner |
| Oct 2, 2019 | Versant Venture Capital V (Canada), LP became a 10% owner |
| Oct 2, 2019 | Versant V Luxco S.a r.l. became a 10% owner |
| Oct 2, 2019 | Versant Ophthalmic Affiliates I, L.P. became a 10% owner |
| Oct 2, 2019 | Versant Affiliates Fund V, L.P. became a 10% owner |
| Oct 2, 2019 | Scott M Rocklage became a director |
| Oct 2, 2019 | Scott M Coiante became SVP, Chief Financial Officer |
| Oct 2, 2019 | Redmile Group, LLC became a 10% owner |
| Oct 2, 2019 | Lars B. Abrahmsen became SVP, Chief Scientific Officer |
| Oct 2, 2019 | KDev Investments AB became a 10% owner |
| Oct 2, 2019 | KCIF Co-Investment Fund KB became a 10% owner |
| Oct 2, 2019 | Jonathan Hepple became a director |
| Oct 2, 2019 | John D Diekman became a 10% owner |
| Oct 2, 2019 | John B Henneman III became a director |
| Oct 2, 2019 | Johan Christenson became a director |
| Oct 2, 2019 | Jeremy Green became a 10% owner |
| Oct 2, 2019 | HealthCap VII, L.P. became a 10% owner |
| Oct 2, 2019 | HealthCap VII GP S.A. became a 10% owner |
| Oct 2, 2019 | Guido Magni became a director |
| Oct 2, 2019 | Gregory Alan Korbel became VP of Business Dev't |
| Oct 2, 2019 | Eyal C. Attar became SVP, Chief Medical Officer |
| Oct 2, 2019 | Development AB Karolinska became a 10% owner |
| Oct 2, 2019 | Christian S Schade became a director |
| Oct 2, 2019 | Christian S Schade became President & CEO |
| Oct 2, 2019 | Bernd R. Seizinger became a director |
| Oct 2, 2019 | Andrew J. Schwab became a 10% owner |
| Oct 2, 2019 | 5AM Ventures IV, L.P. became a 10% owner |
| Oct 2, 2019 | 5AM Partners IV, LLC became a 10% owner |
| Oct 2, 2019 | 5AM Co-Investors IV, L.P. became a 10% owner |
Not reported recently (12)
- Nadeem Q. Mirza · Last reported as Chief Medical Officer in an SEC filing dated May 2, 2024
- Gregory Alan Korbel · Last reported as SVP, Chief Operating Officer in an SEC filing dated Aug 1, 2022
- Eyal C. Attar · Last reported as a director in an SEC filing dated Jun 7, 2022
- Scott M Coiante · Last reported as a director in an SEC filing dated Jun 7, 2022
- Lars B. Abrahmsen · Last reported as SVP, Chief Scientific Officer in an SEC filing dated Mar 14, 2022
- Gregory S. Wessels · Last reported as SVP, Chief Commercial Officer in an SEC filing dated Mar 1, 2021
- Johan Christenson · Last reported as a director in an SEC filing dated Jul 1, 2020
- Jonathan Hepple · Last reported as a director in an SEC filing dated Jul 1, 2020
- HealthCap VII, L.P. · Last reported as a 10% owner in an SEC filing dated Oct 7, 2019
- HealthCap VII GP S.A. · Last reported as a 10% owner in an SEC filing dated Oct 7, 2019
- Versant Ventures V GP-GP (Canada), Inc. · Last reported as a 10% owner in an SEC filing dated Oct 7, 2019
- Guido Magni · Last reported as a director in an SEC filing dated Oct 7, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold APRE
1 shown · $36.91K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $36,909 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.08
TTM Revenue
$5.18K
TTM Net Income
$-12.31M
TTM Op. Cash Flow
$-12.17M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $0.00 | $-3.59M | $-0.07 | $-3.28M |
| Q1 '26 | 2026-03-31 | — | $-3.29M | $-0.22 | $-2.76M |
| Q4 '25 | 2025-12-31 | $3.34K | $-2.46M | $-0.28 | $-2.96M |
| Q3 '25 | 2025-09-30 | $1.85K | $-2.97M | $-0.47 | $-3.17M |
| Q2 '25 | 2025-06-30 | $118.11K | $-3.24M | $-0.53 | $-3.13M |
| Q1 '25 | 2025-03-31 | $162.46K | $-3.93M | $-0.66 | $-3.63M |
| Q4 '24 | 2024-12-31 | $205.82K | $-2.89M | $-0.47 | $-3.51M |
| Q3 '24 | 2024-09-30 | $354.62K | $-3.78M | $-0.64 | $-2.47M |
| Q2 '24 | 2024-06-30 | $561.57K | $-3.47M | $-0.58 | $-3.64M |
| Q1 '24 | 2024-03-31 | $380.57K | $-2.81M | $-0.67 | $-3.94M |
| Q4 '23 | 2023-12-31 | $14.07K | $-3.44M | $-0.92 | $-3.74M |
| Q3 '23 | 2023-09-30 | $319.47K | $-3.20M | $-0.86 | $-2.24M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-12
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.24
P/S
1780.56
EV/EBITDA
—
EV/Sales
-6171.89
ROE
-32.0%
ROA
-29.1%
Div Yield
0.00%
FCF Yield
-131.80%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$9.23M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
508.84K
SI % of Float
4.87%
Days to Cover
2.45
Short Vol Ratio
69.6%
Free Float
10.45M
Float %
83.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14